CRVS
Income statement / Annual
Last year (2023), Corvus Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Corvus Pharmaceuticals, Inc.'s net income was -$27.03 M.
See Corvus Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$151,000.00 |
$367,000.00 |
$460,000.00 |
$632,000.00 |
$743,000.00 |
$847,000.00 |
$842,000.00 |
$594,000.00 |
$148,000.00 |
$0.00 |
| Gross Profit |
-$151,000.00 |
-$367,000.00 |
-$460,000.00 |
-$632,000.00 |
-$743,000.00 |
-$847,000.00 |
-$842,000.00 |
-$594,000.00 |
-$148,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$16.53 M
|
$24.47 M
|
$29.12 M
|
$31.83 M
|
$37.98 M
|
$38.59 M
|
$46.31 M
|
$29.36 M
|
$11.35 M
|
$41,455.00
|
| General & Administrative
Expenses |
$6.88 M
|
$8.10 M
|
$9.52 M
|
$11.93 M
|
$10.88 M
|
$10.64 M
|
$10.22 M
|
$7.62 M
|
$2.42 M
|
$134,182.00
|
| Selling & Marketing
Expenses |
-$151,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.73 M
|
$8.10 M
|
$9.52 M
|
$11.93 M
|
$10.88 M
|
$10.64 M
|
$10.22 M
|
$7.62 M
|
$2.42 M
|
$134,182.00
|
| Other Expenses |
$0.00 |
$587,000.00 |
$235,000.00 |
$37.46 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$17.60 M |
$0.00 |
| Operating Expenses |
$23.41 M |
$32.57 M |
$38.63 M |
$43.76 M |
$48.85 M |
$49.22 M |
$56.52 M |
$36.98 M |
$13.77 M |
$175,636.00 |
| Cost And Expenses |
$23.41 M |
$32.57 M |
$38.63 M |
$43.76 M |
$48.85 M |
$49.22 M |
$56.52 M |
$36.98 M |
$13.77 M |
$175,636.00 |
| Interest Income |
$0.00 |
$654.00 |
$0.00 |
$540,000.00 |
$2.18 M |
$2.28 M |
$861,000.00 |
$601,000.00 |
$35,000.00 |
$0.00 |
| Interest Expense |
$1.58 M |
$654,000.00 |
$15,000.00 |
$540,000.00 |
$2.18 M |
$2.28 M |
$0.00 |
$601,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$151,000.00
|
$367,000.00
|
$460,000.00
|
$632,000.00
|
$743,000.00
|
$847,000.00
|
$842,000.00
|
$594,000.00
|
$148,000.00
|
$175,636.00
|
| EBITDA |
-$26.88 M
|
-$40.94 M
|
-$42.78 M
|
-$5.36 M
|
-$48.85 M
|
-$46.09 M
|
-$54.82 M
|
-$35.78 M
|
-$31.19 M
|
$14,636.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$3.70 M
|
-$8.74 M
|
-$4.61 M
|
$37.77 M
|
$2.18 M
|
$2.28 M
|
$861,000.00
|
$601,000.00
|
-$17.57 M
|
$0.00
|
| Income Before Tax |
-$27.03 M |
-$41.31 M |
-$43.24 M |
-$6.00 M |
-$46.67 M |
-$46.94 M |
-$55.66 M |
-$36.38 M |
-$31.34 M |
-$175,636.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$8.74 M |
-$5.04 M |
-$1.17 M |
-$2.93 M |
$2.28 M |
-$842,000.00 |
-$594,000.00 |
-$35,000.00 |
$0.00 |
| Net Income |
-$27.03 M |
-$50.05 M |
-$38.20 M |
-$4.82 M |
-$43.75 M |
-$46.94 M |
-$55.66 M |
-$36.38 M |
-$31.34 M |
-$175,636.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.56 |
-1.08 |
-0.91 |
-0.16 |
-1.49 |
-1.71 |
-2.72 |
-2.36 |
-1.54 |
-1.03 |
| EPS Diluted |
-0.56 |
-1.08 |
-0.91 |
-0.16 |
-1.49 |
-1.71 |
-2.72 |
-2.36 |
-1.54 |
-1.03 |
| Weighted Average Shares
Out |
$48.03 M
|
$46.55 M
|
$41.85 M
|
$29.48 M
|
$29.35 M
|
$27.51 M
|
$20.49 M
|
$15.42 M
|
$20.41 M
|
$170,000.00
|
| Weighted Average Shares
Out Diluted |
$48.03 M
|
$46.55 M
|
$41.85 M
|
$29.48 M
|
$29.35 M
|
$27.51 M
|
$20.49 M
|
$15.42 M
|
$20.41 M
|
$170,278.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
